Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Behind-the-counter statins: a silver bullet for reducing costs and increasing access?

Sood N, Sun E, Zhuo X.

Health Serv Res. 2012 Feb;47(1 Pt 1):174-87. doi: 10.1111/j.1475-6773.2011.01315.x. Epub 2011 Aug 30.

2.

The case for over-the-counter statins.

Gotto AM Jr.

Am J Cardiol. 2004 Sep 15;94(6):753-6. Review. No abstract available.

PMID:
15374779
3.

Statins for age-related macular degeneration.

Gehlbach P, Li T, Hatef E.

Cochrane Database Syst Rev. 2015 Feb 11;(2):CD006927. doi: 10.1002/14651858.CD006927.pub4. Review. Update in: Cochrane Database Syst Rev. 2016;(8):CD006927.

4.

Does simvastatin cause more myotoxicity compared with other statins?

Backes JM, Howard PA, Ruisinger JF, Moriarty PM.

Ann Pharmacother. 2009 Dec;43(12):2012-20. doi: 10.1345/aph.1M410. Epub 2009 Nov 17. Review.

PMID:
19920157
5.

The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS.

Palmer SJ, Brady AJ, Ratcliffe AE.

Int J Clin Pract. 2003 Nov;57(9):792-800. Review.

PMID:
14686571
6.

Cost-effectiveness of primary and secondary prevention in cardiovascular diseases.

Troche CJ, Tacke J, Hinzpeter B, Danner M, Lauterbach KW.

Eur Heart J. 1998 Apr;19 Suppl C:C59-65. Review.

PMID:
9597427
7.

The impact of reference-pricing systems in Europe: a literature review and case studies.

Dylst P, Vulto A, Simoens S.

Expert Rev Pharmacoecon Outcomes Res. 2011 Dec;11(6):729-37. doi: 10.1586/erp.11.70. Review.

PMID:
22098289

Supplemental Content

Support Center